Evidence map›Paper›PMID 19115012›Full record

ArticlePloS one2008

Genetic variation stimulated by epigenetic modification.

W Jason Cummings, David W Bednarski, Nancy Maizels

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Targeted gene therapies: tools, applications, optimization.Critical reviews in biochemistry and molecular biology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

W Jason CummingsDepartment of Immunology, University of Washington School of Medicine, Seattle, WA, USA.
David W Bednarski
Nancy Maizels
University of Washington · US

Funding

MECHANISMS OF SOMATIC MUTATION OF IMMUNOGLOBULIN GENESR01GM041712 · NIGMS · YALE UNIVERSITY · PI MAIZELS, NANCY · 1990 to 2011
$3.4M
Targeted Gene Repair by Homologous Recombination (Component 8 of 11)RL1GM084434 · NIGMS · UNIVERSITY OF WASHINGTON · PI MAIZELS, NANCY · 2007 to 2011
$2.0M
NIGMS NIH HHS R01 GM041712NIGMS NIH HHS R01 GM41712NIGMS NIH HHS RL1 GM084434
6 · The paper itself

Abstract

Homologous recombination is essential for maintaining genomic integrity. A common repair mechanism, it uses a homologous or homeologous donor as a template for repair of a damaged target gene. Such repair must be regulated, both to identify appropriate donors for repair, and to avoid excess or inappropriate recombination. We show that modifications of donor chromatin structure can promote homology-directed repair. These experiments demonstrate that either the activator VP16 or the histone chaperone, HIRA, accelerated gene conversion approximately 10-fold when tethered within the donor array for Ig gene conversion in the chicken B cell line DT40. VP16 greatly increased levels of acetylated histones H3 and H4, while tethered HIRA did not affect histone acetylation, but caused an increase in local nucleosome density and levels of histone H3.3. Thus, epigenetic modification can stimulate genetic variation. The evidence that distinct activating modifications can promote similar functional outcomes suggests that a variety of chromatin changes may regulate homologous recombination, and that disregulation of epigenetic marks may have deleterious genetic consequences.

Indexed as

Genetic VariationAnimalsCells, CulturedChickensChromatinEpigenesis, GeneticGene ConversionHistonesMolecular ChaperonesNucleosomesRecombination, GeneticChromatinHistonesMolecular ChaperonesNucleosomes

Identifiers

PMID19115012
PMCPMC2605549
OpenAlexW2024746874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.